Regeneron Says EMA Committee Supports Extended Libtayo Dosing
The EMA's CHMP adopted a positive opinion recommending approval of an alternative dosing schedule for Libtayo, Regeneron said. The available report does not specify the dosing interval.
The EMA's CHMP adopted a positive opinion recommending approval of an alternative dosing schedule for Libtayo, Regeneron said. The available report does not specify the dosing interval.